Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation
This study uncovers the immunologic role of TRAIL-mediated cell death in the TIME and provides evidence for the encapsulated cell-based therapy to kill residual tumor cells and induce long-term immunity.
Authors
- Vladimir Vrbanac (ORCID: https://orcid.org/0000-0002-0593-1723)
- Hiroaki Wakimoto (ORCID: https://orcid.org/0000-0001-8225-241X)
- Wanlu Li (ORCID: https://orcid.org/0000-0002-7637-1364)
- Nobuhiko Kanaya (ORCID: https://orcid.org/0000-0002-0427-4426)
- Nicolas Freeman
- Khalid Shah (ORCID: https://orcid.org/0000-0002-5474-0974)
- Kok‐Siong Chen (ORCID: https://orcid.org/0000-0001-5796-5290)
- Lucia Moreno-Lama (ORCID: https://orcid.org/0000-0003-3900-1388)
- Thijs van Schaik (ORCID: https://orcid.org/0000-0002-0516-646X)
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Raymond Y. Huang (ORCID: https://orcid.org/0000-0001-7661-797X)
- Yu Shrike Zhang (ORCID: https://orcid.org/0000-0002-0045-0808)
- Mian Wang (ORCID: https://orcid.org/0000-0001-8311-8394)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Harvard Stem Cell Institute (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3835
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59